About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Nasus Pharma Receives $22 Price Target and Buy Rating From Laidlaw & Company

Nasus Pharma (AMEX: NSRX) has been initiated with coverage by Laidlaw & Company, which assigned a Buy rating and a 12-month price target of $22 in a report dated September 29, 2025. These views and projections are those of Laidlaw and its analyst team, not of Nasus Pharma. The full report is available directly from Laidlaw representatives. As of the market close on September 28. 2025, NSRX was trading at $8 per share.

A Closer Look at Nasus Pharma

Nasus Pharma is developing a dry powder intranasal delivery system aimed at transforming treatment in acute, life-threatening conditions where every minute matters.

The lead program, NS002, targets the $3 billion anaphylaxis treatment market by delivering epinephrine through a simple nasal spray rather than an auto-injector. Compliance with injectable devices has historically been low due to needle phobia, bulkiness, and user error in emergencies. Nasus’s powder spray is designed to overcome those barriers, potentially improving both speed of administration and patient adherence. Early studies suggest that NS002 may deliver epinephrine more rapidly to therapeutic blood levels than current injection-based standards.

Nasus’s approach is not limited to anaphylaxis. The same powder-based platform has already been applied to an intranasal naloxone product for opioid overdose reversal and to a COVID-19 antiviral spray, demonstrating versatility across therapeutic areas. This breadth creates multiple potential “shots on goal” for the company beyond its flagship allergy program.

The competitive landscape is also validating the concept. ARS Pharma’s Neffy, a liquid-based nasal epinephrine spray, received FDA approval in 2024 and has quickly gained market share, showing that regulators and patients are receptive to needle-free delivery. Nasus’s powder formulation may offer advantages in absorption speed, device usability, and stability compared to liquid sprays.

With a post-IPO market cap of around $75 million, Nasus is significantly smaller than peers already active in the space, yet it is targeting a large and growing global epinephrine market projected to reach $6–7 billion by 2030. Upcoming catalysts include further Phase 2 studies of NS002, progress on manufacturing scale-up, and eventual regulatory milestones as the company moves toward Phase 3 trials.

 

Recent News from Nasus Pharma: Nasus Pharma Announces Closing of Initial Public Offering

 

Disclaimer & Disclosure: This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Investing in small-cap and micro-cap securities is highly speculative and involves significant risk, including the potential loss of your entire investment. This content is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Nasus Pharma Ltd for promotional media services provided on an ongoing subscription basis. The exact terms and amounts of this compensation, along with full disclosure information regarding the operator of Wall Street Wire, are available at: wallstwire.ai/disclosures. References to analyst ratings, price targets, market size estimates, or other third-party data are provided strictly for informational purposes. Wall Street Wire does not endorse, confirm, or guarantee the accuracy of such information. This article should not be considered an official communication by the issuer.

Media Contact
Company Name: Wall Street Wire
Contact Person: Staff
Email: Send Email
Country: United States
Website: https://wallstwire.ai/disclosures

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.